HUE030586T2 - Kationos bakterioklorofill származékok és ezek alkalmazásai - Google Patents
Kationos bakterioklorofill származékok és ezek alkalmazásai Download PDFInfo
- Publication number
- HUE030586T2 HUE030586T2 HUE05749886A HUE05749886A HUE030586T2 HU E030586 T2 HUE030586 T2 HU E030586T2 HU E05749886 A HUE05749886 A HU E05749886A HU E05749886 A HUE05749886 A HU E05749886A HU E030586 T2 HUE030586 T2 HU E030586T2
- Authority
- HU
- Hungary
- Prior art keywords
- amide
- oxo
- palladium
- group
- compound
- Prior art date
Links
- -1 Cationic bacteriochlorophyll derivatives Chemical class 0.000 title claims description 80
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 544
- 229910052763 palladium Inorganic materials 0.000 claims description 259
- 150000001875 compounds Chemical class 0.000 claims description 140
- 125000000217 alkyl group Chemical group 0.000 claims description 113
- 239000000203 mixture Substances 0.000 claims description 57
- 150000001768 cations Chemical class 0.000 claims description 40
- 229910052717 sulfur Inorganic materials 0.000 claims description 32
- 229920006395 saturated elastomer Polymers 0.000 claims description 20
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 125000004429 atom Chemical group 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 210000004556 brain Anatomy 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 241000209202 Bromus secalinus Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 101150030891 MRAS gene Proteins 0.000 claims 1
- 101100434851 Mus musculus Lap3 gene Proteins 0.000 claims 1
- 101100366940 Mus musculus Stom gene Proteins 0.000 claims 1
- 101100536763 Mus musculus Tfeb gene Proteins 0.000 claims 1
- 241001247287 Pentalinon luteum Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 241001467018 Typhis Species 0.000 claims 1
- 239000005862 Whey Substances 0.000 claims 1
- 102000007544 Whey Proteins Human genes 0.000 claims 1
- 108010046377 Whey Proteins Proteins 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 235000015241 bacon Nutrition 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 235000014121 butter Nutrition 0.000 claims 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 claims 1
- 238000002485 combustion reaction Methods 0.000 claims 1
- 238000009264 composting Methods 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 101150010139 inip gene Proteins 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- 230000001020 rhythmical effect Effects 0.000 claims 1
- 239000004065 semiconductor Substances 0.000 claims 1
- 239000008279 sol Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 402
- 150000001408 amides Chemical class 0.000 description 214
- 239000000047 product Substances 0.000 description 170
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 162
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 114
- 229960000583 acetic acid Drugs 0.000 description 113
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 102
- 206010028980 Neoplasm Diseases 0.000 description 101
- 238000004128 high performance liquid chromatography Methods 0.000 description 95
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 94
- 239000012300 argon atmosphere Substances 0.000 description 82
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 76
- 239000000243 solution Substances 0.000 description 75
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 70
- 238000002428 photodynamic therapy Methods 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 63
- 230000014759 maintenance of location Effects 0.000 description 62
- 239000012071 phase Substances 0.000 description 62
- 238000012790 confirmation Methods 0.000 description 55
- 125000004433 nitrogen atom Chemical group N* 0.000 description 42
- 229940125898 compound 5 Drugs 0.000 description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 38
- 229910052760 oxygen Inorganic materials 0.000 description 38
- 125000001183 hydrocarbyl group Chemical group 0.000 description 37
- 238000011282 treatment Methods 0.000 description 37
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 125000000623 heterocyclic group Chemical group 0.000 description 31
- 150000003839 salts Chemical class 0.000 description 29
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 28
- 238000007098 aminolysis reaction Methods 0.000 description 28
- 238000000746 purification Methods 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- 238000010521 absorption reaction Methods 0.000 description 24
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 23
- 230000004962 physiological condition Effects 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 230000003287 optical effect Effects 0.000 description 20
- 150000001450 anions Chemical class 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 229940082150 encore Drugs 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 16
- 206010034972 Photosensitivity reaction Diseases 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 16
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 16
- 208000002780 macular degeneration Diseases 0.000 description 16
- 108010013121 palladium-bacteriopheophorbide Proteins 0.000 description 16
- 208000007578 phototoxic dermatitis Diseases 0.000 description 16
- 231100000018 phototoxicity Toxicity 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 206010064930 age-related macular degeneration Diseases 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000003504 photosensitizing agent Substances 0.000 description 15
- 230000008878 coupling Effects 0.000 description 14
- 238000010168 coupling process Methods 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 14
- 108010003118 Bacteriochlorophylls Proteins 0.000 description 13
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 229940012017 ethylenediamine Drugs 0.000 description 13
- 229910052751 metal Inorganic materials 0.000 description 13
- 239000002184 metal Substances 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 125000002837 carbocyclic group Chemical group 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 125000000524 functional group Chemical group 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 208000032612 Glial tumor Diseases 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 9
- 102000007562 Serum Albumin Human genes 0.000 description 9
- 108010071390 Serum Albumin Proteins 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 125000004430 oxygen atom Chemical group O* 0.000 description 9
- 125000004076 pyridyl group Chemical group 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 125000004434 sulfur atom Chemical group 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 229940125773 compound 10 Drugs 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 238000005286 illumination Methods 0.000 description 8
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- HTDIUWINAKAPER-UHFFFAOYSA-N trimethylarsine Chemical compound C[As](C)C HTDIUWINAKAPER-UHFFFAOYSA-N 0.000 description 8
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 125000000129 anionic group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 210000003038 endothelium Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 150000002772 monosaccharides Chemical class 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 150000004032 porphyrins Chemical class 0.000 description 7
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 7
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 208000037803 restenosis Diseases 0.000 description 7
- 229960002317 succinimide Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 6
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 6
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 6
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 6
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-O Pyrazolium Chemical compound C1=CN[NH+]=C1 WTKZEGDFNFYCGP-UHFFFAOYSA-O 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- 230000002137 anti-vascular effect Effects 0.000 description 6
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 6
- 229940125846 compound 25 Drugs 0.000 description 6
- 229940125844 compound 46 Drugs 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 6
- ZCQWOFVYLHDMMC-UHFFFAOYSA-O hydron;1,3-oxazole Chemical compound C1=COC=[NH+]1 ZCQWOFVYLHDMMC-UHFFFAOYSA-O 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-O hydron;pyrimidine Chemical compound C1=CN=C[NH+]=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-O 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 229910052748 manganese Inorganic materials 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 6
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 5
- VUEDNLCYHKSELL-UHFFFAOYSA-N arsonium Chemical compound [AsH4+] VUEDNLCYHKSELL-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 229940126142 compound 16 Drugs 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000002189 fluorescence spectrum Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- AWJUIBRHMBBTKR-UHFFFAOYSA-O isoquinolin-2-ium Chemical compound C1=[NH+]C=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-O 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 125000002971 oxazolyl group Chemical group 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 4
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 4
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 4
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 4
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 4
- 229940126657 Compound 17 Drugs 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- 229910052691 Erbium Inorganic materials 0.000 description 4
- 229910052688 Gadolinium Inorganic materials 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 229910052769 Ytterbium Inorganic materials 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 125000000909 amidinium group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 4
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 229940126179 compound 72 Drugs 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 150000002390 heteroarenes Chemical class 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- TYHXIJJQIJKFSO-UHFFFAOYSA-N n'-pyridin-2-ylethane-1,2-diamine Chemical compound NCCNC1=CC=CC=N1 TYHXIJJQIJKFSO-UHFFFAOYSA-N 0.000 description 4
- 229910052759 nickel Inorganic materials 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 4
- 229940109328 photofrin Drugs 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229910052718 tin Inorganic materials 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 239000005700 Putrescine Substances 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000002586 coronary angiography Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-O hydrazinium(1+) Chemical compound [NH3+]N OAKJQQAXSVQMHS-UHFFFAOYSA-O 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000002892 organic cations Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 125000005496 phosphonium group Chemical group 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- UCQFSGCWHRTMGG-UHFFFAOYSA-N pyrazole-1-carboximidamide Chemical compound NC(=N)N1C=CC=N1 UCQFSGCWHRTMGG-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
- FZQXMGLQANXZRP-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(3-imidazol-1-ylpropyl)thiourea Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)NCCCN1C=NC=C1 FZQXMGLQANXZRP-UHFFFAOYSA-N 0.000 description 2
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- FXESYRVBOSQTDD-UHFFFAOYSA-N 1-n-pyridin-2-ylpropane-1,2-diamine Chemical compound CC(N)CNC1=CC=CC=N1 FXESYRVBOSQTDD-UHFFFAOYSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- GJBYCNLSIBQCRF-UHFFFAOYSA-M 2-aminoethyl(trimethyl)azanium;chloride;hydrochloride Chemical compound Cl.[Cl-].C[N+](C)(C)CCN GJBYCNLSIBQCRF-UHFFFAOYSA-M 0.000 description 2
- IKNKRQDYANBMHT-UHFFFAOYSA-N 2-dimethylphosphanylethanamine Chemical compound CP(C)CCN IKNKRQDYANBMHT-UHFFFAOYSA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010070075 Bacteriochlorophyll A Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 240000008213 Brosimum alicastrum Species 0.000 description 2
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 206010072960 Chest wall tumour Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 208000006787 Port-Wine Stain Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- XSZWYZUVMJWNBB-UDTOACJGSA-N chembl3109097 Chemical compound N1C(C=C2[C@H]([C@H](CCC(O)=O)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C(C)=O)=C1C=C1[C@H](C)[C@@H](CC)C4=N1 XSZWYZUVMJWNBB-UDTOACJGSA-N 0.000 description 2
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GSOLWAFGMNOBSY-UHFFFAOYSA-N cobalt Chemical compound [Co][Co][Co][Co][Co][Co][Co][Co] GSOLWAFGMNOBSY-UHFFFAOYSA-N 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 229940127113 compound 57 Drugs 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
- YOTZYFSGUCFUKA-UHFFFAOYSA-N dimethylphosphine Chemical compound CPC YOTZYFSGUCFUKA-UHFFFAOYSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002710 external beam radiation therapy Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 125000000879 imine group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- 150000002503 iridium Chemical class 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 208000018223 neoplasm of chest wall Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- GPIVNYFDHQDTDZ-GDUCSYRESA-L oih1h7cjcj Chemical compound [Pd+2].[N-]1C(C=C2[C@H]([C@H](CCC(O)=O)C(=N2)C2=C3[N-]C(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C(C)=O)=C1C=C1[C@H](C)[C@@H](CC)C4=N1 GPIVNYFDHQDTDZ-GDUCSYRESA-L 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 231100000119 phototoxicity / photoirritation testing Toxicity 0.000 description 2
- 125000001189 phytyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])[C@@](C([H])([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 235000005828 ramon Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241001598984 Bromius obscurus Species 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 101100326341 Drosophila melanogaster brun gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VZUHQRBBQSLSHS-SSZFMOIBSA-N Isoimide Chemical class C1=CC(Br)=CC=C1\N=C/1C(CCCC2)=C2C(=O)O\1 VZUHQRBBQSLSHS-SSZFMOIBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 1
- JYQAZWPSIIKEGO-UHFFFAOYSA-N [2,2-bis(ethylamino)hydrazinyl]ethane Chemical compound CCNN(NCC)NCC JYQAZWPSIIKEGO-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- RQBBFKINEJYDOB-UHFFFAOYSA-N acetic acid;acetonitrile Chemical compound CC#N.CC(O)=O RQBBFKINEJYDOB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000320 amidine group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- LHIJANUOQQMGNT-UHFFFAOYSA-N aminoethylethanolamine Chemical compound NCCNCCO LHIJANUOQQMGNT-UHFFFAOYSA-N 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-O aziridinium Chemical compound C1C[NH2+]1 NOWKCMXCCJGMRR-UHFFFAOYSA-O 0.000 description 1
- 150000004036 bacteriochlorins Chemical class 0.000 description 1
- XZSVAMUZTKNGDN-JBRJOJLESA-L bacteriochlorophylls Chemical compound [Mg+2].[N-]1C2=C(C=3C(C(C)C(=CC=4C(=C(C(C)=O)C(=C5)N=4)C)N=3)CCC(=O)OC\C=C(/C)CCCC(C)CCCC(C)CCCC(C)C)C(C(=O)OC)C([O-])=C2C(C)=C1C=C1C(CC)C(C)C5=N1 XZSVAMUZTKNGDN-JBRJOJLESA-L 0.000 description 1
- KWOZSBGNAHVCKG-WFDCHTCOSA-N bacteriopheophytin a Chemical compound N1C(C=C2[C@H]([C@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C(C)=O)=C1C=C1[C@H](C)[C@@H](CC)C4=N1 KWOZSBGNAHVCKG-WFDCHTCOSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- YRPWLKVCRKAUAO-UHFFFAOYSA-N bismuthonium Chemical compound [BiH4+] YRPWLKVCRKAUAO-UHFFFAOYSA-N 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 1
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 1
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 1
- 229930002869 chlorophyll b Natural products 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-O hydron piperazine Chemical compound [H+].C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-O 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- ANSUDRATXSJBLY-VKHMYHEASA-N methyl (2s)-2-amino-3-hydroxypropanoate Chemical compound COC(=O)[C@@H](N)CO ANSUDRATXSJBLY-VKHMYHEASA-N 0.000 description 1
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-O morpholinium Chemical compound [H+].C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-O 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- CEFDTSBDWYXVHY-UHFFFAOYSA-N n'-[2-(diethylamino)ethyl]ethane-1,2-diamine Chemical compound CCN(CC)CCNCCN CEFDTSBDWYXVHY-UHFFFAOYSA-N 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- QHJABUZHRJTCAR-UHFFFAOYSA-N n'-methylpropane-1,3-diamine Chemical compound CNCCCN QHJABUZHRJTCAR-UHFFFAOYSA-N 0.000 description 1
- RAJSAPSERUGCBT-UHFFFAOYSA-N n'-pyridin-2-ylbutane-1,4-diamine Chemical compound NCCCCNC1=CC=CC=N1 RAJSAPSERUGCBT-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100001085 no phototoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 108010049593 padeliporfin Proteins 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 125000003367 polycyclic group Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003283 rhodium Chemical class 0.000 description 1
- SPVXKVOXSXTJOY-UHFFFAOYSA-O selenonium Chemical compound [SeH3+] SPVXKVOXSXTJOY-UHFFFAOYSA-O 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- XZKQVQKUZMAADP-UHFFFAOYSA-N serinyl-serine Chemical compound OCC(N)C(=O)NC(CO)C(O)=O XZKQVQKUZMAADP-UHFFFAOYSA-N 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- HISNRBVYBOVKMB-UHFFFAOYSA-N stibonium Chemical compound [SbH4+] HISNRBVYBOVKMB-UHFFFAOYSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- VTLHPSMQDDEFRU-UHFFFAOYSA-O telluronium Chemical compound [TeH3+] VTLHPSMQDDEFRU-UHFFFAOYSA-O 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (9)
- mmmMa* ês εηκαιιοαιμΜβαι SZABADALMI IGÊNYTOÎÔK:1, Rí) MiéPöS kèpii bakipokit Ml PlâBbpéèsm- sN -3? 8^ ÍBPP ÀépiffeëB Mjpkmtésp OH, sgy kêtéstékB a kéaétkpgêk kMÁPiassÁsi jk|; Pi PL Ορ,ίΑ Mi, Ri Soès- Mm Pagpegy hárorpéfíéká#n8Ím; prppigp á|spíko;# kökoLvaisaiai kk pocii Ri Am AL SA.: Ib Yb es CM 8¾. W$ ès Rs pMn&s ëpAàîîM SBpgMisfis ^%,-N%^vap:#8^A§s#§it:. V JMeatése ö vagy S alom: Rs JefeÂe 'CH-CRRkA. -CR-CRji-ML -GHMLH-CKM-âRÿRA iH®€H-CM^PMiAJk%A·. -OHO. 4ό®Μ% -ΟηΜΥΜ^Α CHjORí; -OA-Sk;. -CH^HaL -CH>Rr -CH^R^ iH?-R-P<:RkRAÁ. ÍHoCHAA. .OHí-CRAM' ••Cîà-CH;:ORa 'CHí-CHjSR$. 'CH>CH>RRíRS. .CH?-CHMARiRAR':;:A\ -000¾ -CfCHp^SMRM CrCHp-CRenO •C;CHg=CRv:1a?, GfCHs)-MR% 0HP0}*i1%R|Aç -CHlCHg-HaL ·ΟΗ(ΟΗ·ρ·ΟίΟ. -ChsCHR-SR;. ·€Η(0ίΟ;·ΡΗ0Μ. ••CHfCHgdkARRYAYA· vogy -OCR& csoport: %i%: κ:ιόο R'S jorsroése ogyr'oasíói &iggetenöls:k&vsfcE§ MÁM: <>j )A Ibé G^GísSssohMrogáii ibiikbÄesopÄ ic; 0>Όλ saanbimps ΡίΡηΚήΑόί) ésspéi óióyéssn €sg aik:RosöpoRt einyésstiBéo Oms sjkiöiggstb még MőnydssBbort 0<4 MkAosöpoti amely sààsÂàMâ lÉét^ ^ több AmkÉrs ssopspi, emiyek a követeik. keik «teftÖ- kit'hsia^fete, nis: smp OR. SR este epéi, s Andin. -CO?vRP\ -COR: COöR. -COSR. OSO.-R. “SGtR,. SCbR, ^HSÖÄ ^isPRs ^RRR', teöR: P NRiRt AZMNRf-RG’RÁ NR-RRTf, RR}N^CmNRFNR1L ű*te&s >ΜίΚ φφΗMm, tete-G&tefA teiCHteCR -Ο-iCidíS.-O-rCHpv'R. OPO;;RR', #QSHR; -OCoRR'.. «sgy ebi n ogéss snsrn Mőí bég.. R és R: és Rteinflse egyrtiástoí föggéliénbj R Mte vagy stebiíogén (bidMksftsÍ) esopsilvagy hateroPiki-OSOpPíL vagy Rte és R" koyüi köti o|yb!tteal as N stems!* ateyte M tagi; tokié gyámi képednek, -m4f klvárs! esé&ao tehakna* agy vagy sdöb válbésmsiok «. ü. $«$ N, «s ks^áat esetben sa&sÄa&s leket tovMïpà a további M osos^s'e btyâb »ιβ*δ·<*ορ« h», ?!;kry meg 8iisbsaiiss;àiv.s tehet helngèr^oînnips és klmo*· vágj amsssO'tsopöfÄ (d) Cs'CïssœedÎKiiog^ ífó*ökat>=i) csoport előnyőse Gi «eisii-csoporJ· eiöeyöoeböen 0' :'S&3-e$oport, még aâéayôsablXîf* C·;·« aikli<sopob. aseosy oaibsrlltisaivs lehss eoy vagy lo»3o tuekivos csosorUoi. asnsiyek pozitívan iostôn csalok ko/ot vslssäkasök ki. mégpedig a kővetkezők kezűi vésasztnstők ki: is) égy olyan araum csoport, smoky ίϊβϊ« tshsims?. hi Siofor (is) kakor·, asysety js-sapaimé csoporteos szérm&ok mo kation, ama!)'· oiysn nesefos mmès vegyeseiből sz&msÄ aboi gs salairssk egy vagy R-esoyi;ot as (ovásst. esetben 0 vagy § atomokat vagy negatives'; töltött osagottok kMik yätss&hssök ks 8?ss4phek gélaáska következők: COO·: COS.. OSO'. PCs -OFösR. 'PO.Hy POs*\ és -PO-O. vagy bözisos csop-ono* *ó2bi ;y^!É|]i||áFBk'WÍ>S Ä1 ksmioéápk· kètèi, aspf /o/O-Or rwxi'ti.·!' pro., CovRoo. \-?oSrtw,c* \ í\Hví \,”V'" VíR 'íR R4XH t ** \ Ct-NRyRR'Rt ö«~NR\ >ONR, vagy agy Némtslmó hetefociklissoe gyök ahol R R! ős R' jelensése a *c) :|k3h:ibsn PépÂk k$#l v'É^ttii^'loőíTltiy# kPhprOióöhgk:pgaioah lókök osőponokka toolőgsöa kesvmenvek kóiolk s-mely savas esooosíok a kővetkezők «öash vamszmmők -CQÔH, -COSH -SOjH, é$~P(m fa) 0^«8Â^n;pà?â^i|'iÈ^^|f#8y^p'-:C^ maskv-osoposi ektnyösePbess C^sÄksegost. Olg ÄyösgbBes &$ iikssopö snse| feiste agy· vagy Ä hetestosrfe efeagy egy vsgyifeh héteffefeses gyâkiymoiefy); : (f|ï iiOpOgíilPehidíogéé (bfesksfet eshfetf ::eifeyêssn Cp silfeppsfe Λ|^|φ^,·0^ρΜ?δ^ρίΙ· srég előnyösebben C»·« «îi'esopfe amely saRate; sgy; vsgy Mhb hetoatest es/vagy egy vagy több karhociklyses vsgy heteroctklosos gyököt és sstefeőtva van sgy vagy tfeb fekfes csoportiek ahogyan etek as előzőekben aie) és (d) pontokban am|;fetok hateva; |g| OeOisShiklfopé (hfeokarbtl) oso-poé. előnyösen Ci a= alkk'esopog. eiônyôpô>én C:.i*aikll-cpprt. Ihég eíőhyőplph 0?« aikiKsopP, amely stobstiliiS vál ómlppay gyökkel, peplisdel. lehegéve:. mo!K.stschaédd.ei. ollgosischsHdla; vagy polsstacharidös;. vagy ih) amieesav gyök, ppko, fokege, monosyaekakd. o%ptaof>arO vagypHtaeoseö, lapep^ie S - i^gyi^isàafe«. ' iâggô^e?îôi- Y-Ra csopoíi; rRRopleglös# ^rnYesöh;, sfkméelihiaiiek ya|f eiyätertes käli| A· ieieeïése Ptlolögialieg eiogadhsté selon, se érlêko s) vagy 1; ès mlndeaek llxioléglallag elfogPhalè i#|s pkks> t^cmegei. astâi a leiOteiiei. hogy s fîl) àMeïss képsek; Pskssseoklofoil: szármst^nak veo legfőbb egy poïvlivas Ι4Η|Ρ ospoflls ésfvagy iepObb egy öliéöe csoposga. aseesy kökysroiplk egy pejïîivso tökölt csopoftió felo^iéo kssölrfeVsyek között
- 2. At I. igénypont sseds^ bsktenekiorolsll ssârosazèk. ekps M lesés-ïSs# 2|l :|.pt íkiphypont syeéstti bskterloklosolISi s^msat^, ehpl M lesébtéss Föl
- 4. At 1/Igénypont stesmti bsktorioklos'olsSI sséssösték, . 4 A 4, Igénypont szehní! bsksoeoklofotlii stő^asék, shot as·· amely R-taftalnig osoporOó! ssärmaglk, ahol ez n kóv>>tkeaök k|tO vélsatsheto ki- N-(RfOV) \ > -N \R oo p ^'\ mRR .-.}, s X '' X ' v<' «\ x:;îv ' vt-0 H.M , ' bskfelÄrsi! äxseHuls s^énhkù'ogfen *teokssiJij őelót hotyifckeö·« si. Or Az ik abcs a? amllioU salibo -N^RR'R't ska^ios képlete ammemum esoport.: Äi R. »fl^l^^iWpkfae^ÿmôsto: íö-ggesonu? hidrogénatom {MdrokarN csoport, aümyöseo C:.s-s!kjâ-3Speii siSsyêsebb&ii&s âiii-esoport he^oc» csoport vagy R. R’ és R' közül Kettő *&»$ vasi Μ KRatömsiaÉ, -amelyl^rföpife^iamtalg $=7-1^:¾¾¾ gyOíöt Kép&ZfiSk. «meiy Kívánt esetben tana-maz eoy ^gy t&'-fc liÂ^^à^m-.àefeiÂkMi.aiÂÂ ki.. &:$.ès H. és Kivált esetben sztibszteoái*a «-hei a ü atomnál. g·? legû telített gyûni s kováié»:· kásái váieszttiaté si. azimtio. pmol-d-o, prpendkp modality komodolin, ezopio és piperazla. smeiy&k a tovabOi NistaSI ksvèm esetben szuoezetoasva vasnak €ι*(λ eiké-csoponiei. amely klvsst ésetbèa «antül -^mbszMu^v^ vba hsiogensbmma; vagy hidroxti- vagy amirso-soopofrps ο « li-b-np^"* -eV» sipx" v'H^y P> eiN y< ^ v I ié ébbegv -> - 1 a J\j v% e* £\,> v >* " amely egy heteroatemas csoportból származik, ahol es tartalmaz egy vagy több R stomot és krvlst esetben u ee o atomokat. amely kation a következők közéi vaisszíbatö ks pírazokum. imtoezotrom. ô*a20$|gs, %$$$&$% pÉmbisMi Kiaotsmem. aeklneilmam,p;íimiömsyfn, 1,2,4vííta#fiiiim, 1,3.&'R<vof:::.;rn es paomomkahon 9. A 4 i§eoyeo«i szinti btttaMtitrafil származék. ahol as emtlfe« tegaláöb egy pózéivá tökéé csínon egy oosom vagyéiep smery a következét; kézét völasztírstó R •OlRR·, .5'(RR'}. -Sr{RRv}; -V(RR·}. ^íRRIT*-AríRRI**}. -SblRR^} és -Bi'tRR'RR, aboi R, R' As R* mindegyAènek jstetése egymástól lügqafenoi hidrogénatom. szenhktregen {bsörokasbii} esősort oiôr.yooee C< rttfkte&ort. előnyösebben C: * atkíksopod. meg előnyösebben C»« cikkcsoport és hefetodMH· csoport. tö Ar ; igénypont es*?<nt: tm^tenoklorettlt szónnazék. amely tayfpfoss Rgaiébé ogf rbäkRSS ooPpöÄ aboi «s sacoerátóíiik postlvan tokoít csosorké kboiogiés boruioroisyoy között;; ti A10. igénypont ssaonb bakte?«kiofoéü szérfeazék, sho; az as «mssteu iogoiéPo Agy bázssos ceoport: s?o%íy bnygtifegik posévaa tőitek csoporttá tosoiogAs Potóiraónyok között, egy Raartaiau; hetsroa:o:oá$ gyök. amely à sovotkotok közút yÂeziofé ki' piîâzoiik ImKiazoi, exsz^l tiasoat. pem. ««nőim! szoAosiimi. p*êm«dll. R0.4-toazieé 1.9Λ téaomt ss »jnoe gyök; 1? Az I igénypont szebep bstktobokiorsflii szém>o.?ek aboi R%. .¾. Rs. R'» és Rk- ezàfittidfogèe {hidrakarferl} eseport. stöeyöeép sgyeoes vagy ekàgazo tàîîeà C*-Ch cikk táeo vagy CoC*. alkoea iérso. Âyôs^wt Coicaïktbçeoeork még elêeyès#bea Cva alkrt^seppft, amelypk kRébt eseéien taflalmaznak egy vagy Jobb tiefereatomelosmelek a iëvmkezôkiIMltvéiesibstôk Ki O, S es Ki vägy tietereslkteses gyökkel geosetyl,:
- 13. Az 1. igényporé szsréeti bakterioktorofö számtazék. «íréi MjéÉetéeeJH vagy RP: :;Rlz|efeeïèee-ÔRa.:abot R.i jeiesttéso -COCHü Rí jeiotttéseai ^NRsRvvagy -NR^Crf^ChOH)- C RrOH Rpptoelss «sR'y vagy #îRîîHî-CH(OH)-CHzOH. RyjetgÄse Rámgy Ci c a&is-^spftpés (bidrmcarbíi; csoporr: ámeiy szébsatitulivs vae sidgáiébb égy pzltvatt tokot; ásepöRíss ïegaisbe egv ckv3ü t*;v. s.'í cses.'ixüas pv.ab.aa '«Hab csapói*; î;ixàx”âv köíülreéíívek ksæoît H a 13. i§éí;ysx«ií ea%f^U bskexiohfcseib; ss&fr-aÄ aboi R> jsSenles® H ès R's iefeefëse C;-C» ÂS-esopeR. eRayàsehba« €; <« sik$ksöp&íl még eRkT^esbbeo C-.« älfei-csopoft. smá) %£ubszt^vs can legalább egy 'NlRRíX} pozitívan lökött csopoRtal vagy laga'seb ogy -RRR! l'á&eos esinxcttal. és kivált esetben c'eg van szakítva agy -H(RV esseeriUst, aï;oî R as R' yslenbho egymástól luggotlene; H. Ü<<, sRa-csopoR. asoely Kívánt csatban szobsztltoálva van MFfrV-vei. vagy egy hetesecmR csapost. nw* pisákat ptbpibosopost. vagy R es R' «gyütba* M alostxna; sgy haUagö gjötüt; i;í:s>eíxeR amsky tataiam továbbá O. S vagy H akxnsX, es R' matése Hyagy 0¾ sttdbcsosxei 15 A13. i$é«ypoM sxeriftfc bakteilot'fcrofiii sípszók. ahoi Rí shoyetkesok *&& vàiaaatnaiô ki' 0H; -NHR's és -NH-CHa-çhçOHÎ-CHXsh. es Réclamées egy -Hm*&*%><&. asoeíy a kövessék köss® *®aszthst6 kl: tO 'RH'iCài'-k-NRR'' vagy RkHH€H4-R-RRR\ Ölt -RH-(CHí) .-R(R'R|CH4^Ä m|:ν|:: és fV''i shoi a képletekben X |!epse 0. $ vagy MR; k:Rf ^ ég %^Α H «gy c,. m<m*% $mwÉ®rnmm ícm9. előnyén m dkg. es ?n «tèk* egész Síám 1 -Ri S % e^ydsae t -Ri 3-tg. 1M15. »MÄS5»«eemi3»sii «Mfcisaisi «,*<«*« *«·** »? * «-»' W» » là 32-vei i^iölt vegyük tó* várhatók ks Μ»*» ^ 0 *» s®gyiM} Nä&i ^ ^ ^ vâgÿ&eQ Paüáükiffs 3 1 1 *>*»!«», Jt»xc>.*»wtte#*laJ« 85 FÂIsÉiÂMMMéShéÂMieSFI^^ÂÎÂyiSN^i^^^^^'0·^^^^' Ρ&ϋβ 3 ÄiÄÄiiililMiäWiÄ * 3’..pp'hä^di#ksm!n&-s5!?)- am?noHi^?i Ä ssgyÄ Vkgyislst! V? Λ 13. k;<5!n>;üïiî $?o?i«b &&&$?!($&*·>&* skálái**: sko: R- |«&ρ$5£ -NHR'Sí l§ az itt é11.'Sís-! j#Ä ős SMI'i'Si jÄ v«g5Ú;iítí,8·; Közűi cátóhekM* 3^x»-t5-i^W^Döfi^«n§?k-Ro^olÄÄ^i>>lSRlT^^-^Mkme^-s^moríig^-et^-s^i áfelí: :M, || ydspNil) 3,^xo-tS-môH»*'kart»ïïé-nïSt^-Riïdoti^leni»aor»>-,s3ï. 1T'-GK3-<s»«ttn&*£>r^0}'^«4 (jg v%öy»'í*eíí ^^xo-1 -1 T^ :<IK.3-^iMomefei'ôr?Knî^:UïV!«|>rû«^)-ainkl distil # ff fegyufeí) 1 Τ'-öné- -<# ¥®g?ü!*i :#|fe'ií S§ i|: vi9|úte| PaBáöíaro 35- ox!->' 1S-ΐη^ίο>··.*- kss-D-^nk-r?íeíí^P<^>dc k-erk>?<:^r;ri' 1 ^^ ?'s-ci;í xís ;me^ï'Sín-rso- îîuïyî'etsäclbsHsl műmnél Pilácsaim 3<'OX<h^5*m^»-H«n50wKmi-RoiteaR*8m>te^ä^^^i^dl{2'N^»l!^i^!ni^i^^fi|^Ä êscsÈI Poksds1·’^ :·^ ;0l-^?'híí-<i;ÍM}i!*íKíi>fSí>-s^}'í»nkí $36vsgyűle^ PsBädto?« 3ΐ-oxO"IS-móttí-«-^aitjon--meTs-^oöobö^tenc-î*o:sn-13 J, ^-íáu^^x-<ismei«-îîïî:Ιίΐο-pföpiíj-aríííü (3? vsgyüist) PÄSüm '35 ο&Κΐ iVoxkCx -k& ixs;^··. no* -R-^obafe^O^ ; \ Z K i ? ä^:(^{2^m!no-ebt^«rpfßs|-ebi}-^ri|d Of #§## Pdiliam 3%;sfd$xitixkkílPípp%p!|tk#^ PMâd^m 1 * '-^p-s'f-o^ho-N-d'^P-air^d ;40 v^Qyv)^?} i^<;xo·1δ·^e)t^ wwá-^Rod^te)kbf^\y\ <41 yegyufcS ÉâiMisiîs / il :y6§yûfe|( PÄ5‘Uitf 3'<>x&-UPm&î0>.rk5:tx)ni^:Ti4;iï'^oL-3X^n,-kS0i·^ W i?>>>»{[:^:Vir^,rr».-i5'eft|)-^-r!i!]-%t· ; amid s43 ^egyíM) Palàdiufi! 3ϊ·<ΐΧθ·1ίν^ίήθί^43?^ο;«Ρ^Ρ^ίΒδΧ;Ρί!θΚί«ηηΡΡ\'ί''ϊ'άρ^Ρ^Ρ~ρ:Γί3ΐ^βίηίηο-*;^ρ«τ;:3 (44 ve^yüieï; PdäadRrn 3s-0^->-1δ-fne'iiîjfs-Ksriîoriââ-Redobakkídokioíáv' i\ ; ' M < 2 -N-Mist;;^ íno-eR )-sirad (4| y®gyüiel£. 13.,» 15. i§8fîyp!>nî äsebnb bak^noXiorai $24fmz%k} »sol Ri jela-rstése 'NH'CH^CHiOHVCHiOH es aboi s vxgyigotgfc sz m#c3l gfr* m*\. M:B $>&’. HW* & *&s4 *»«Kft*ok R PafckiiUi a y-ùfÀr 1 S^etow'ksffcomBttefci -RodohafctbdoRorsiv 13' -(2-smsno-ehO^id'l P-(2:3 <48 vesyûtep Màôâum 3'-oxd-l5-n>^dxkk:sH3öplRpbkfÉpstaM :p;op|í-3íi's;i.1 (|g vggyafet; psnâdfo^i'pfopî^-ô^d: i|§ vegyüfe|);( ÍMadium ,â?4i/iû-î5'?rÂti>«s?te8^^iï^^lÂti^«(Â'13t'(2>H-(2!'î>«Â)v8?^gQ^g|imj(|. 1 7Μ2,3·<8Ν!!<κ;> p^lrÄ® vegyíti 111¾ 3Roxs-1iidliiÄÄi'aP8§PifebasÄ^ Rdibdiurri ^‘'όχο- 15-:¾s^rox:-«bo:>îï RodobaK^iKik^i^l3,^^^0^.^rSp;;^ sd;cj <60 W$p$% «MurriS'^^^to^-k^^l^^Rodobâk^kîr^l^^^^^ps^d-îT^^^nidfi^â'Pr^ij.sfnid RsgMuw ^PxöiSdlsiaÄ^ p-ôpig-amsd {§2 vagyaiéi) and« (§! vsgyùâeî) ^îâSiuts 35 -îîsç#- 1 rOöOii'ms ^13 ^<^5('Π;ίόϋ-0?ü 3 a^?oî€Î': 2^: Oihidissäs : propïii-gmi (64 vagyaiéi) Palládium 3Ρ®<ο4δ«*0Μδ?&»#^ ^hkiroxi-propsIH^d i?1 veggie*} Palládium 3,<>x«4e-îfie^x?-ss!îKmà-r^i.po#«Nfe^13,-(4^P(^.p!i^!|).â?tH^^p^0.ir'4j3.. Pihidroxkpfopî!)^eiifi (O vagyaiéi), 1:1 i:ν|3: iiPpig S|pnii: ΜΜί S2ádX:32«k: alx>! Rí (eleggsa -RH-CHs-CHiOHICHíOii |s:Ríjeibiés# ^RR| csípő?!. és ;*r*?:y * követők kôxbi válaszíba* k ·] 4yH -fCki'd.'RRR' fagy 'NHaCH^-ki-RP'S* (=1) -RH5CHpc.'N1K r(CH.i„'NRR': :i? SSshoi s népietekben X ietmnèee D S vacty MR, R. R' es R?|slebiâ»s sgérsMôRsgplIeeûl H vsgy CPs alkOesopoé. n e-leke eges? seam 14¾ ;0 :g. előnyösen 2-röi 6-:g: és m emlke epésé seam l-ki 0 <; előnyösen táp 3d|k SPATSI: !oénveörits:éereé!Íé3sienekÍore“ll seâmwèk #p a úsgyáistek iít 46-tot, <|pei. jg-cel. SMi-gyel. SS-mk 58-caJ, Il-má és .M-gysi leiéit vogyúístsk koaél vaiasSkätsPkn: Palládium: 31 -esse 1 iS:SsetööRäriessäi'«äet:lnRodobakieöekloök':i ?x|2^iffleiik :smoíénkíOí-eöí| -síssá (|| sgpyôia| Palládium: 3Roys-'1S'0$eteXrSerbssyno§kl'Roüobakiesok!Sfis--ISix22*diöldesyä^fopiikOOkövtTSp2.gspjiö^kg-srk|d lÄiis à^xo^ISsmsIô^^âr^oteéfeRyafeâklsMtelé'-IS^p^'dÂmxbpre^l-a^iiâkl^l'ft^-ôkiPR sislno-elpaîold ill vegyefet) Palládium: 3Rsys-'iS'iT!8tsxsRa?beoil'Sseki-Redöbak!edekloPnR:six2:2ielhldröyi-pfoei8'Ossiösl?X|2--p-snkse>eö!k aminopeíliiosmlé ill smgyüieii Palládium 31msS'iSmm!oxl>kaífesn!kmeíli-RssöéakfelsssaslO'ööso2;3'-dlhlsmómsoplÍimoád'-1X5i2-(í3-Rkdiotí· ^Ιην·«·:0··3-·η:;χ:]··δ^η·«η;·5 (§g gigySRP Pafigdlgm #pas?âd: 111 vggyöMf PaíjMö ss : IN» 16'i5)eiöxs^Ä5NQs^it^rieiFRö£i0föö^^!iökteHi^-1S^''(^,#N;i^Ni:»^^P:?;öp;|ii-^sTiM:'i N- gllpsfïdd Hl vggyiMf PaliÄss: fit'**P$si| Psliädlsjäsr S^-ssiî-i s-ïÎs^ÏOs^ksibôïiâ^iîs^iiï^R^sïfeaktfeîiô^silfs^13^'C2,3'<S;hidros|-'^f<;»i|}'gifnM' ï ?^'(|S--bs^C2^«s^&5i>> sli|-räSÄNi|safsid (II vsgyinep PáláP» •^»liifsstsÄäitaissssÄQ^lÄfiS^ÄytlNSy^^o^^NnÄl^^fl^g.NÄ^' amlïs-prôpi^smsd (Ü vsgyatei) •P«(!#top· 3îd3»t§N%e;lal4Ea^«Riiiî>3lî^aàôbakfer5pfelsN4l,;^,3NÂô.^Pî©|^|s-gîSid4?^{4^('2>^iêli)« NiNfetINÄ (Μ vegyidé:;, 21 Ai 1. igé-sypo?·· ssennii bakiedckfeoA: seèe-sasè*. .she! M ΙρίρηίΐΜ 2Η ysgy Pd; R3 ;ÍgPÍSíí -0¾ «h<2 RsjRsrddsg CvCs ämAsggpM, eldayôàe» P5PÍ-sssps?| Rí|d;Mtésë COCH>. RíjSienidse MH-CHí-Chí-hRR·, $a R; aAi#t§ai23ö2ÖI váNálfía® k:t 'RRA|ÇH?j:s-ôR; .RH-CH(Oh}-CHv A#v(üHjP-HR-îCH/):OH: As giNKiNA^pHisdpôA; anoi R As P' plesÎéM ^fAàsIi RggglRN; Hs meid vagy eHesepest ésà êR#p 2 vágyR. 22/Λ21, Igdnypppl '#èl A ydgyietsii sali fMikssi ès ||ρρ! jaM vPgyiledR kê$i yiaSMssfpl R: >-a X ! O1 Oa. *>( -.RmS·-'' M i '\ Ό ^ ''f' -i * s gAàd (M vágóiét Fâ:iad;um 3;-OioRSaHsioxina;tionsasaH-FodoOökRriükionsA3:'(2'hP'di;ssü!'ar;i;riü'al2)-3rn;d-1F':3 niaroA- progiparAki (Il wgyäkRj íAsSddHSV: d'^sOFa-a^i-icHAkailHas-^eR-PsCiaDákíenoFonaAS^ Ad-Hi-dls^tii-s-s^iO-'etSi-ansd· 1 Γ'·ί2.η;Α·ί>χ:. prpgíg-gmld ||7; vegy|fe| Pglddpp S !-o:so· 15'iaa:aA-kansHsPa';8H'RsdöSsa;e?byí0AnA3-;2.sp.i:iiiT:S-!i-aH:ií!0''eH}-a;B;a· 17Α(Ρ|·2>Α stöA· progiii-smia (§8 vegyüied PalMlpm 3:·«χοΑ6^%·οχ;-κδΓδοηΐ!·Γ?;8ΐ·ΑΡ5αοΡ»Κ;8ΓΐίΡ;ο;!:ν13'72-Ρ2·2:ΓΒδ21·δϊΤ«ί«·8Ηρ^:ηίΡ-5?πρ3].2.^;<;:ν!Χ;. prsgRasgdd (l|v8gyú(p| Paliádiurn 3:-oso-15asaiCí;-karbcaAaiei;;-Podob82t8rioAcH;n' 13: · (2 - N c 1 í>n>í? ; d-eRI-esn-d-l 7:iA2-(2-!sdrex:·®;;· aípiíSö^si^sfsM Hí yagylM) PadMiPiT:: 3!-d;sp43aps:^ 12 S|2-MSNls^^í?P^í^sf!ö^ts7}^íí'iAí;'1 ?A(gfeRRsmld IM wgsíssii
- 23. Aa i sgéí^ypoPPagitai, (3| âMSags kdgRld éákRdpRöSAii 88«m58íék. sM M isfeatM®1 2H vagy Pd, F2 peeféss - Sil f?s IfèiÉsïlës# 0 i-fös l-íSSSípöí tr ^Ör^öSfen ^sil^^pof I ; R^ pä«^!@s#: - C50C Hs, és Ri ^NRi=sR^: ahoi R$ ponièse H és R's jelentése OC* sz&th4fo§&> feferokartőí; osopost feonyôsoo D walkst-csoport. efeoyésobbsr! Ci OrSlh·;·-csoport. még előnyösebben G:, s aikiktsoport. serei y smrsytiàiâRa van egy osoportiat. ahoi s? a keva-kerfek Ko?.·.« választható ki: ό} goanickno- vagy gotK-doioordopoh: .$ SAntonferO'Csoporf; (ül) íosshoo· vagy fesAonfern-osopod à-, (p . grií.iíiíss*1· ysg5v<::^ráö Γ?>-·;^:>|ΐΐίΐ?ϊ,;: 24 A ZSÇ) igénypont %z£t'mh baklenoktorontl syármppfedip gyiàpipfefenfêse a kovs^o fipikkéi É&éji^ppprt: -RH-(CHj G -C( " Hh j- MHj vagy *NH-<CH?Ka/NH}-N*(»}5Ä, shot R jelentése Ch aiklhosoposi, eior-iyösstt moüksoport n értéke égés? szám 1-töi 18-ig, e^nyös«» 2,3 vagy & és A' jelentése egy anson, '6 A <.4 !»·«·:0><ι i,3fcW*.Uv5.« k«.-.Sa«. a-oa·, A. .0 14 W» 14a jetons *> ο <c λ lvv.iOtos. o4> v» Rsilèdiom 3-tsxo*1S-fííetííXi-K8íbooí!'fa«iK-?íí^>áKteí«3í'Ayin'15'',i'?5-<íi{2-í?irsfeSii'§ií3ítiíSiftkííVi>3r!í---83'ild ; 14a yegyeiel). 2€. A 23psï fénypont szónak oakfedovkyold származék. ahol R·· à s Asjoremése ake«etk«2ê kèp^ts! festő osopoti 4ίΗ>· sinyosen 2;ί3 vspf t: ès À7 jofetifeee egy séfen. 2? A2¾. :§éf*ypon!szstm« óakfehcRfet^itssátoiPzéfe smoly 8? ni ISjeiofesáiitréye® $M PsBt&Kn 3*-<»ο-1 ^S^'îS-^i^fï^^^ïSi^ÈÂàèSïÎiSH^J-aiïÎKi errat so (1¾ vofpferj .. A·23<Ιϊ’ϊ'i^hÿpc^'to^eî^i^.stirmázek, shsGRi is tijéfenlésë;äiiKSveS^sörfe^i^gEfefei.:^-1^.:êsbg^ïtp-.ÎÎ#*:^^ :pHïpRpÿ:: ÄtpPp à, BÄ# MpÄI Ä '»ftt; efytkr ^H'pRí^-P{CHs}:i és :s^P||a#|i|^f: 0" vosobe '*'v H ·* * 1 V 'S ' Μ V* . Γ > -3 *\ ! vw ^ " >' * ' Î Λ *"· s?*' N 3 wgy 6 sa A pk-oks* nd> e -eoar on oxoot^sgn ont ' Ο* , < S *<-· i '<>«'0 v. ^ !v'< szv*· a n nz G1K' <B V .'"Svc l> ^ R' ^ ' Äko-lö-ihfeopÄ^ iSÄ: M: ül yecyuioü 3RgP-1&feefepk;ÉtrgbihfePI-RP^
- 33, A SâM'^.:^i\Vpi^li;S^ânÇ ^Sáí|^öHÍ9ÍfS>^H ZZéovp:?#.. ahoi ahoi R: és SMil AöVéikepÁipfeW óké csoport: * NH-iCHj)ft-As(Rî -, előísyésen a következő képlettől b«0 csoportok eoysko: -RH-{CHír-AsíCh:ó; ón -NH-iCKäv-AsiAijÄ. ofenyosotboo s kővetkező képfetiet ovo csoport -fe-HCH.'WAv{CHn>A\ aboi n értéke ooos? s?è?n Uô* ^0-¾. eiSapsoo 2. § V8§yô,ès Ai pénifie ogy eifenaoiso (cooofemnions 11. A10. sgésypoPlszsifek bskfedoKtoroSs származó, «neiy az 1| iefeiéssoi bitó vogyùfei: :)'-osí> ?CHpeto,s:-kort'OOii'n>síARoJR5afeesokior*o-131·!:-5fes(2 AsA fetnoi· -o^fefffiifP-ot.lAasokl d elhat so (j| vágyóiéi). isi: A? 1. igènypoo; yzeriot; pi) skofenos képleté oahtonokiorobi; ezèmvazék, séol Ai jsieniéso 2H vagy Rdt kg jeieovstsS · ORs. aboi Rspeotèso Cs-Cs atkii-csopofl. eionvossn sasdi-csopon. R* peoteso -C|CHí)~HRí·. ás Ri as/vag? Ríi^eaíéséK . ssjftöü .^¾¾ ^iZ^irrhsdiH^i^fr ^hicí előnyösen ÇoAàïiIôSgpôR. #5fe:iKS5Si?^^;,:ils^shp#?t^^söbg?s::ös>Ai^^fe«söpöat,:3msl^:.:SSÄÄs egy amsno vègcsopoiltai. 33 A 32. igénypont szenet: hak-enoMorc-ii ssànossôk . aboi R: pontes» 4|Gl|nÍpÜjÁR|i|; |li|s R«tT:índsolií#n«kjüsniéso p|i-(Sk|^INIp Js n àP#S:sees? szao: Mol ^0-¾. siönyosen 2. 3 vagy* iX 33. ssenerl bakhshokloroP; varors ®^y ^ Il fe; I! Passai vegypefck «2^' i ia).i'*t„^. '·ν'ινο·ΐλ'Ί t^'^' '’ )s.?^ vagyak^ 35 te 1 sge^ypcfli «enrsg, {üj $$&*» képiéi irtftrtoMwo* SïàmfâZÈ*. s*mî M moto* 2H yag? PS R* jeler.k&e -OP,, ahoi Psjekîftfese C-Ce a!M*«opart *^#s«o weSkcsoporl R< ascèse -CiOHji-NR^ & R- &je?sifi*«e · Ν>ΤίΡ'ΐ ahol R1 - pienièso H Si s R,. es R\ jéiea?és>e CvC:·* sjpnhklrogéo pRirosah)! csoport, oioayosan C'.. iJk*«we&t ts^:#syoé§^ Cu *M.oscpfe1. é?n*i>- s?nbs?h1ya5v$ van scgaiàt-n 8Çjy pozitter» iô«8ît csoporiîak 3s’ a 35 <#*>?»» «aft* b^tehokio»*; $ùmm&. ahoi «&*ηΒΜβ súÉtot* »tt csoport W ^ », **?"* Λ ÍVÓ -I«1' R P X-'" "V >H A'* 5 "Sv. >'s* ^ R » egy saiöh :3? :R 3#: â^èîÎÿp£S?Ît S£S?l^tPty£S^feriÖMiOSXíííHI ^S^S2^ki:;^tolí:S%i|i&iaí^|sa $$ iky R^hRiSiS -Μ4~: (CHR-PCRirA. eiônyôsen -MH-(CH.-5s-^(C«i)vA absí Epiafeéss CvCs alkli-aopoit. n értéke sgäss um Mos 10-59. ^onyossn 2,3 vagy 3. ás Λ-pontés* % 33 A 37. igénypont s*«i»ü bakPíiokiorofi s*árm*ék. amsty ai 5¾¾ és S3 jussai fere vágyénak agyiba erika Ql vs-gyálst) ipalàrëuro :' •arcmfetsu«^$Hmki (2| vcgyöiag. 30 Gyogyasssu koalíció, amely tsfteknes egy (iS) Maises képtep M; 1ä igénypontok Iif58?yikä S^nfef '&«Xi£Hökkwfi származékot. Os egy gy6§yét?^^0<fá0lW^tíó^i fc»8É| ^Mmri|i^^,íifí8^-i^ Il 'mmm mmmmmmm mw&* mmmm$ mm^ 41A 3¾ îpfprïMmk gpgpsaah kompozíció
- 42. Gyógyásza* kompoaicié a 41. igényi szenna Âmàüiâi vagy bsktsnokferoii származék 8 40 igénypont szefiétl 3 kàoazasm. aofe az estait fotui8>ai>*i,s "ev-jpsa »aswfenyt e&zô <bkxfewfr-Hus teàpsà ivaseieas-taígeerq phaRbyosmu Ihöíöpy (VPT)].
- 43. Gyógyászé kompozíció 0 41. vagy 42. igénypont szerinti a*g5?a»zasra. ahoi az említőit iotoőshanvkas terápia iumorok. ifötfeJioamte. kaílpsp.;
- 44. Gyógyászati kempozicto a 43. igényperé -szerint s&afmasás.^· vagy bakmiokiomtl származék a 40. vagy 42. ^rpoot a;-c V 3ka ?a^a *"' ? * v viN^r» · >\"'\' .1 > '-. όε sltèialos feroooaket. ^si^yek a kovs&esök Kc-aiv va?ss?.tha!ok ks' jyseteïrôïaa. prosxta^a. agy., fp. nyak. yastagS-ài, paíeíásjak. fne» Ή meükasi fsí fesnorok. amsäyok me^ákbó; kemiosrs eiö, Oóf. kidó, nyelőcső és hólyag rákok, és egyéb bormnn-éí'iéksny u;r?sos'oP ^ Sîànnasàk a 40 vagy 42. igényper« S?éb|i slkäipaillrli/iife ié|iaagés foiodinstnikus toîégiép. «h A41 vagy 42 :gorsyp·'.·;« ο#4ηηϊ; gyógyassak ki'hspïifîô. vagy as 1-38 Igényponisk Mras^ke s^eanl· aakiersoklófóhí!-s;iérn-saor a;Ka:mar;asfa sasv- és érfg^esxsfi iseiaosegek íasaieséfe^ ások so?.a éîtve a véi^őó;ry eiioaiődési Ívessé: :06SWöJ% ííi bamSöZíVl a SslÄSJSgÄ' bnmgssgekb&n, a béibnibértya hlpgnvazl-é bnbnmi nyperpissss). g msztsnoss; è$ : aä ÄssÄrntifes piakkokab : m: :À gyászáé itoæpszisiO «s & sakmnokiorokii származék 4«. igénypont wink mot a s-nv- ea énendwl befégségsk emJiM fcaael^^^-«:-e^.^3^|t:!:jr«s®?. vagy ctókkon^e a iáimban i^nb történő reWrmzis? frn »I rmXonnsim WkDszorèér sníángmiiáí kovsiOso. 41; A#tiO?a|y 41 igénypont szennti gyógyászéi ksmpmekl vagy az 1-38 igénypontok bármsiyíko wink bahtéímkloionii I; éőváikMék Itó valaazíba&st ki: pmsnls ^s«e|is ; pSïénéès negesédès (atme scaring), pskkoiysomon gombsa iStsotepség (aádsSa's ?<*>& szomc>ics; Âifeisë^ssc lasli^ersiosts) és ixzp'os fcnok ;porwm stain). y> '* VpO«> ’Sí."'"' V kv v. 'tt> P J' i-X· H-' ^ *' f'pí WH i. '\ ' s2àhïï#®sH aïfes^f sagäsm , r è ri öís^^rí à; i apofen as lésé ben, amasyt* a kowsmazw koad vS^^aÄ'^iikSÄWya, és :^H|i:':PalÉ^^^#^Íyp^tiilkÄ-iÄÄl^ nopyaseoipnzatioo}. és korra? rjâ^ mskmadagonorsotP f pgp-#is?§d msoyiardögsnexiiioo iAMÜiy :§g: 1 vagy : él-: igénypont szon-X: gyégyészék kompozíció. vagy él 1 -38. iptt y |X?PI# éliÉiyikn élPPni PÄbPkionpi: származék blkdiblpÄ : Wör diagnózisban $i_ ά 39;.. ' vagy éí 1-3«. igpypoPtók bómxtiysks szerinti baktoPokiore*: származék sepk vagy olyan km-χο Hl^se* m y te eomsztiipsém. arnalyek bgkeénumokís ss virusoKsi 52 Az Sí igénypont szsrinl gyógyawí somgoztoó vagy bnk&dnHoroli származék sépk vegy ölpéJéddzó agensez sn vüm eipssztäsPA onxiys» ínx-gnonxrkst és vsmsoksi mxaimasnak, egy oiotóoioi wmé^im a? emüléu k^s?· maçvliàg&àéa*^' miornsnebon} arm az amipnü omlást kxmtk. eiOnyOssn vér
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57719604P | 2004-06-07 | 2004-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030586T2 true HUE030586T2 (hu) | 2017-06-28 |
Family
ID=35044538
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10012927A HUE031075T2 (hu) | 2004-06-07 | 2005-06-07 | Kationos bakterioklorofill származékok és alkalmazásaik |
HUE05749886A HUE030586T2 (hu) | 2004-06-07 | 2005-06-07 | Kationos bakterioklorofill származékok és ezek alkalmazásai |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10012927A HUE031075T2 (hu) | 2004-06-07 | 2005-06-07 | Kationos bakterioklorofill származékok és alkalmazásaik |
Country Status (19)
Country | Link |
---|---|
US (1) | US8207154B2 (hu) |
EP (2) | EP1753457B8 (hu) |
JP (1) | JP5372371B2 (hu) |
KR (1) | KR101191700B1 (hu) |
CN (1) | CN1980661B (hu) |
AU (1) | AU2005251556B2 (hu) |
BR (1) | BRPI0511909A (hu) |
CA (1) | CA2569675C (hu) |
CY (2) | CY1118194T1 (hu) |
DK (2) | DK2322173T3 (hu) |
ES (2) | ES2602204T3 (hu) |
HU (2) | HUE031075T2 (hu) |
MX (1) | MXPA06014326A (hu) |
NO (2) | NO339304B1 (hu) |
NZ (1) | NZ551845A (hu) |
PT (2) | PT1753457T (hu) |
RU (1) | RU2397172C2 (hu) |
WO (1) | WO2005120573A2 (hu) |
ZA (1) | ZA200700169B (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2008665A1 (fr) * | 2007-06-25 | 2008-12-31 | Steba Biotech N.V. | Formulation injectable pour thérapie photodynamique |
WO2009107139A1 (en) | 2008-02-27 | 2009-09-03 | Yeda Research And Development Co. Ltd | Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors |
CA2846011C (en) | 2011-08-23 | 2019-10-15 | Yeda Research And Development Co.Ltd. | (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders |
PL2971026T3 (pl) | 2013-03-11 | 2021-06-14 | Tookad Ip Sarl | Sposób wytwarzania bakteriochlorofilu a |
RU2548675C9 (ru) * | 2013-05-29 | 2015-11-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) | Аминоамиды в ряду бактериохлорофилла a, обладающие фотодинамической активностью, и способ их получения |
JP6218073B2 (ja) * | 2013-11-26 | 2017-10-25 | 国立大学法人群馬大学 | 細胞・組織内酸素濃度測定のための高感度近赤外りん光イリジウム錯体 |
RU2549953C2 (ru) * | 2013-12-25 | 2015-05-10 | Федеральное государственное унитарное предприятие Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") | Фотосенсибилизатор для фотодинамической терапии |
RU2610566C1 (ru) * | 2015-09-17 | 2017-02-13 | Сергей Сергеевич Брусов | Способ фотодинамической терапии локальных очагов инфекции |
CN105424857A (zh) * | 2015-12-01 | 2016-03-23 | 浙江汇能生物股份有限公司 | 一种二甲基半胱胺盐酸盐的高效液相色谱分析方法 |
US10836774B2 (en) | 2016-11-30 | 2020-11-17 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
WO2022115443A1 (en) * | 2020-11-24 | 2022-06-02 | The Regents Of The University Of California | Mitochondria targeting quinolinium-drug conjugates and their self-assembling nanoformulations for cancer therapy |
CN115093422B (zh) * | 2022-06-15 | 2023-06-20 | 西北工业大学 | 一种基于代谢标记策略的新型光敏剂及其制备方法和应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3050296A (en) * | 1960-12-19 | 1962-08-21 | Trimborn Hans | Transport roller for industrial furnaces |
US3203888A (en) * | 1961-04-24 | 1965-08-31 | Exxon Research Engineering Co | Treating athabaska sands utilizing a flotation gas |
DE2018970A1 (de) | 1970-04-21 | 1971-11-11 | Badische Anilin- & Soda Fabrik AG, 6700 Ludwigshafen | Verfahren zur Herstellung von beta-Aminoäthylsulfoniumverbindungen |
US5330741A (en) * | 1992-02-24 | 1994-07-19 | The Regents Of The University Of California | Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors |
US5744598A (en) * | 1992-06-19 | 1998-04-28 | University Of Toledo | Imines of porphyrins, of porphyrin derivatives, and of related compounds, and pharmaceutical compositions containing such imines |
IL102645A (en) | 1992-07-26 | 1998-02-22 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
US6147195A (en) | 1993-07-26 | 2000-11-14 | Yeda Research And Development Co., Ltd. | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
IL116126A0 (en) | 1995-11-24 | 1996-01-31 | Yeda Res & Dev | Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them |
US5770730A (en) | 1996-03-08 | 1998-06-23 | Health Research, Inc. | Synthesis of carbodimide analogs of chlorins and bacteriochlorins and their use for diagnosis and treatment of cancer |
HU228208B1 (en) | 1998-12-09 | 2013-01-28 | Yeda Res & Dev | Palladium-substituted bacteriochlorophyll derivatives and use thereof |
IL133253A0 (en) * | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
US6573258B2 (en) | 2000-09-27 | 2003-06-03 | Frontier Scientific, Inc. | Photodynamic porphyrin antimicrobial agents |
AU2002312154B2 (en) * | 2001-06-01 | 2008-05-15 | Biolitec Pharma Marketing Ltd | Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture |
US20030203888A1 (en) * | 2001-06-06 | 2003-10-30 | Boyle Ross William | Chromophores |
AU2002336637A1 (en) | 2001-10-03 | 2003-04-14 | Miravant Pharmaceuticals, Inc. | Chlorin photosensitizing agents for use in photodynamic therapy |
CA2462508A1 (en) | 2001-10-03 | 2003-04-10 | Miravant Pharmaceuticals, Inc. | Photosensitizing carbamate derivatives |
DE10154436A1 (de) | 2001-11-07 | 2003-05-15 | Rodotech Gmbh | pyro-Bakteriopheophorbidderivate |
GB0130778D0 (en) * | 2001-12-21 | 2002-02-06 | Catalyst Biomedica Ltd | Novel compounds |
BR0304716A (pt) | 2002-05-08 | 2004-07-13 | Yeda Res & Dev | Método para formação de imagens de mri-bold on line, sensibilizada |
WO2004002476A2 (en) * | 2002-06-27 | 2004-01-08 | Health Research, Inc. | Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy |
IL152900A0 (en) | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
-
2005
- 2005-06-07 PT PT57498867T patent/PT1753457T/pt unknown
- 2005-06-07 BR BRPI0511909-0A patent/BRPI0511909A/pt not_active IP Right Cessation
- 2005-06-07 AU AU2005251556A patent/AU2005251556B2/en not_active Ceased
- 2005-06-07 NZ NZ551845A patent/NZ551845A/en not_active IP Right Cessation
- 2005-06-07 CA CA2569675A patent/CA2569675C/en not_active Expired - Fee Related
- 2005-06-07 KR KR1020067025726A patent/KR101191700B1/ko active IP Right Grant
- 2005-06-07 MX MXPA06014326A patent/MXPA06014326A/es active IP Right Grant
- 2005-06-07 PT PT100129279T patent/PT2322173T/pt unknown
- 2005-06-07 EP EP05749886.7A patent/EP1753457B8/en active Active
- 2005-06-07 HU HUE10012927A patent/HUE031075T2/hu unknown
- 2005-06-07 US US11/628,719 patent/US8207154B2/en active Active
- 2005-06-07 ES ES05749886.7T patent/ES2602204T3/es active Active
- 2005-06-07 CN CN2005800185365A patent/CN1980661B/zh active Active
- 2005-06-07 DK DK10012927.9T patent/DK2322173T3/en active
- 2005-06-07 ES ES10012927.9T patent/ES2602460T3/es active Active
- 2005-06-07 JP JP2007526692A patent/JP5372371B2/ja active Active
- 2005-06-07 RU RU2006146677/04A patent/RU2397172C2/ru not_active IP Right Cessation
- 2005-06-07 WO PCT/IL2005/000602 patent/WO2005120573A2/en active Application Filing
- 2005-06-07 DK DK05749886.7T patent/DK1753457T3/en active
- 2005-06-07 EP EP10012927.9A patent/EP2322173B1/en active Active
- 2005-06-07 ZA ZA200700169A patent/ZA200700169B/en unknown
- 2005-06-07 HU HUE05749886A patent/HUE030586T2/hu unknown
-
2007
- 2007-01-05 NO NO20070083A patent/NO339304B1/no not_active IP Right Cessation
-
2016
- 2016-09-19 NO NO20161485A patent/NO20161485A1/no not_active Application Discontinuation
- 2016-10-27 CY CY20161101099T patent/CY1118194T1/el unknown
- 2016-10-27 CY CY20161101097T patent/CY1118203T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE030586T2 (hu) | Kationos bakterioklorofill származékok és ezek alkalmazásai | |
US10780045B2 (en) | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | |
US11826426B2 (en) | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | |
Chin et al. | Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer | |
CN112263566B (zh) | 白蛋白结合型缺氧氧化双响应性复合纳米粒、制备方法及用途 | |
AU2019249628B2 (en) | Bladder cancer photodynamic therapeutic agents with off-on magnetic resonance imaging enhancement | |
Siwawannapong | Development of functionalized organic nanoparticles for cancer diagnosis and therapy |